These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

851 related items for PubMed ID: 16959581

  • 1. Hypertension and diabetes: role of the renin-angiotensin system.
    Jandeleit-Dahm K, Cooper ME.
    Endocrinol Metab Clin North Am; 2006 Sep; 35(3):469-90, vii. PubMed ID: 16959581
    [Abstract] [Full Text] [Related]

  • 2. The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications.
    Cooper ME.
    Am J Hypertens; 2004 Nov; 17(11 Pt 2):16S-20S; quiz A2-4. PubMed ID: 15539106
    [Abstract] [Full Text] [Related]

  • 3. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K.
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection.
    Abuissa H, O'Keefe J.
    Diabetes Obes Metab; 2008 Dec; 10(12):1157-66. PubMed ID: 18494810
    [Abstract] [Full Text] [Related]

  • 8. The renin-angiotensin-aldosterone system: a pivotal role in insulin sensitivity and glycemic control.
    Perkins JM, Davis SN.
    Curr Opin Endocrinol Diabetes Obes; 2008 Apr; 15(2):147-52. PubMed ID: 18316950
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Role of the renin-angiotensin system in the endocrine pancreas: implications for the development of diabetes.
    Tikellis C, Cooper ME, Thomas MC.
    Int J Biochem Cell Biol; 2006 Apr; 38(5-6):737-51. PubMed ID: 16198140
    [Abstract] [Full Text] [Related]

  • 12. [Microalbuminuria is an early marker for increased morbidity and mortality].
    Bramlage P, Wittchen HU, Pittrow D, Dikow R, Kirch W, Lehnert H, Ritz E.
    Fortschr Med Orig; 2003 Feb 27; 121 Suppl 1():28-32. PubMed ID: 14732947
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The evolving story of the RAAS in hypertension, diabetes and CV disease: moving from macrovascular to microvascular targets.
    Steckelings UM, Rompe F, Kaschina E, Unger T.
    Fundam Clin Pharmacol; 2009 Dec 27; 23(6):693-703. PubMed ID: 19817870
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders.
    Krum H, Gilbert RE.
    J Hypertens; 2007 Jan 27; 25(1):25-35. PubMed ID: 17143168
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep 27; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 20. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
    de Zeeuw D.
    Semin Nephrol; 2007 Mar 27; 27(2):172-81. PubMed ID: 17418686
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.